2022
DOI: 10.3389/fnint.2022.896400
|View full text |Cite
|
Sign up to set email alerts
|

The “Loss” of Perineuronal Nets in Alzheimer's Disease: Missing or Hiding in Plain Sight?

Abstract: Perineuronal nets (PNNs) are chondroitin-sulfate glycosaminoglycan (CS-GAG) containing extracellular matrix structures that assemble around neurons involved in learning, memory, and cognition. Owing to the unique patterning of negative charges stemming from sulfate modifications to the attached CS-GAGs, these matrices play key roles in mediating glycan-protein binding, signaling interactions, and charged ion buffering of the underlying circuitry. Histochemical loss of PNN matrices has been reported for a range… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

3
34
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 30 publications
(37 citation statements)
references
References 69 publications
3
34
0
Order By: Relevance
“…Future studies are thus warranted to assess the downstream mechanisms by which CCR5 normalizes gamma power and cognitive endpoints in the APOE4 TR mice. Potential approaches include interventions that specifically target the ECM (Dubisova et al ., 2022), and examination of ECM proteins in fixed brain tissue from individuals with and without APOE4 with care to account for potential differences in glycan sulfation (Logsdon et al ., 2022; Scarlett et al ., 2022). In addition, since APOE4 may increase the risk of recurrent episodes of major depression, a disorder often associated with reduced gamma power and cognitive deficits (Khalid et al ., 2016; Papp et al ., 2018; Alaiyed et al ., 2019), future studies may be warranted to test CCR5 antagonists for this disorder.…”
Section: Discussionmentioning
confidence: 99%
“…Future studies are thus warranted to assess the downstream mechanisms by which CCR5 normalizes gamma power and cognitive endpoints in the APOE4 TR mice. Potential approaches include interventions that specifically target the ECM (Dubisova et al ., 2022), and examination of ECM proteins in fixed brain tissue from individuals with and without APOE4 with care to account for potential differences in glycan sulfation (Logsdon et al ., 2022; Scarlett et al ., 2022). In addition, since APOE4 may increase the risk of recurrent episodes of major depression, a disorder often associated with reduced gamma power and cognitive deficits (Khalid et al ., 2016; Papp et al ., 2018; Alaiyed et al ., 2019), future studies may be warranted to test CCR5 antagonists for this disorder.…”
Section: Discussionmentioning
confidence: 99%
“…Recently, attention has also focused on the role of PNNs in the control of neuronal and synaptic plasticity in health and disease [ 359 , 360 ], it is now clear that PNNs also have important roles to play in cognitive learning processes and the modulation of memory. Disruption in PNNs has been observed in AD [ 361 , 362 , 363 , 364 ] and with increased levels of Tau pathology in neurodegenerative conditions [ 365 ]. HS-PGs also have roles in the deposition of pathological protein aggregates in brain tissues [ 317 ].…”
Section: Function Defining Properties Of Hs-pgs and Cs-pgs In Neural ...mentioning
confidence: 99%
“…In addition, overstabilized PNN inhibits the growth of neurites and restricts the signaling transmission between neurons and synaptic plasticity [ 173 , 174 ]. Other work has reported the remodeling of PNN glycan structures in AD [ 175 ]. The chondroitin-sulfate glycosaminoglycan (CS-GAG), which is attached to the CSPG proteins in PNN, illustrates sulfation modifications in AD and results in the remodeling of PNN [ 175 ].…”
Section: Ecm In Neurological Diseasesmentioning
confidence: 99%
“…Other work has reported the remodeling of PNN glycan structures in AD [ 175 ]. The chondroitin-sulfate glycosaminoglycan (CS-GAG), which is attached to the CSPG proteins in PNN, illustrates sulfation modifications in AD and results in the remodeling of PNN [ 175 ]. The treatment of AD model mice with ChABC reduces Aβ plaques' deposition, restores synaptic density, and alleviates AD symptoms, such as LTP impairment and hippocampus-dependent memory loss [ 176 ].…”
Section: Ecm In Neurological Diseasesmentioning
confidence: 99%